386 related articles for article (PubMed ID: 3260909)
41. Increase in tumor necrosis factor-alpha mRNA but not perforin mRNA expression in response to two newly characterized anti-LFA-1 monoclonal antibodies.
Hommel-Berrey G; Bochan M; Brahmi Z
Nat Immun; 1994; 13(6):301-14. PubMed ID: 7894201
[TBL] [Abstract][Full Text] [Related]
42. Isolation and characterization of cytotoxic granules from human lymphokine (interleukin 2) activated killer cells.
Lowrey DM; Hameed A; Lichtenheld M; Podack ER
Cancer Res; 1988 Aug; 48(16):4681-8. PubMed ID: 3260817
[TBL] [Abstract][Full Text] [Related]
43. Membrane-associated lymphotoxin-expressing lymphokine-activated killer cells up-regulate intercellular adhesion molecule-1 expression on target tumor cells in vitro.
Kimura K; Abe Y; Horiuchi A; Miyake M; Kimura S
Cell Immunol; 1995 Aug; 164(1):119-25. PubMed ID: 7634343
[TBL] [Abstract][Full Text] [Related]
44. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
45. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
46. Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations.
Ballas ZK; Rasmussen W; van Otegham JK
J Immunol; 1987 Mar; 138(5):1647-52. PubMed ID: 2879870
[TBL] [Abstract][Full Text] [Related]
47. Lymphokine-induced cytotoxicity: characterization of effectors, precursors, and regulatory ancillary cells.
Ting CC; Yang SS; Hargrove ME
Cancer Res; 1986 Feb; 46(2):513-8. PubMed ID: 3079663
[TBL] [Abstract][Full Text] [Related]
48. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.
Ballas ZK; Rasmussen W
J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892
[TBL] [Abstract][Full Text] [Related]
49. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
50. Monoclonal antibodies against leucoagglutinin-reactive human T lymphocyte surface components. Two antibodies which inhibit cell-mediated cytotoxicity at a post-binding stage.
Vargas-Cortes M; Hammarström ML; Hammarström S; Hellström U; Perlmann P
Eur J Immunol; 1986 Jul; 16(7):795-801. PubMed ID: 3522246
[TBL] [Abstract][Full Text] [Related]
51. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
52. A murine very late activation antigen-like extracellular matrix receptor involved in CD2- and lymphocyte function-associated antigen-1-independent killer-target cell interaction.
Takahashi K; Nakamura T; Koyanagi M; Kato K; Hashimoto Y; Yagita H; Okumura K
J Immunol; 1990 Dec; 145(12):4371-9. PubMed ID: 1979586
[TBL] [Abstract][Full Text] [Related]
53. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
54. T3 monoclonal antibody activation of nonspecific cytolysis: a mechanism of CTL inhibition.
Mentzer SJ; Barbosa JA; Burakoff SJ
J Immunol; 1985 Jul; 135(1):34-8. PubMed ID: 2582036
[TBL] [Abstract][Full Text] [Related]
55. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
56. Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity.
Paya CV; McKean DJ; Segal DM; Schoon RA; Showalter SD; Leibson PJ
J Immunol; 1989 Jan; 142(2):666-71. PubMed ID: 2536060
[TBL] [Abstract][Full Text] [Related]
57. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
58. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-7 selectively enhances natural kill cytotoxicity mediated by the CD56bright natural killer subpopulation.
Dadmarz R; Bockstoce DC; Golub SH
Lymphokine Cytokine Res; 1994 Dec; 13(6):349-57. PubMed ID: 7535569
[TBL] [Abstract][Full Text] [Related]
60. Induction of cytolytic activity by anti-T3 monoclonal antibody. Activation of alloimmune memory cells and natural killer cells from normal and immunodeficient individuals.
Suthanthiran M; Williams PS; Solomon SD; Rubin AL; Stenzel KH
J Clin Invest; 1984 Dec; 74(6):2263-71. PubMed ID: 6392343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
